Novartis Secures Key Regulatory Win for Flagship Drug

In a strategic move to bolster its core pharmaceutical business, Novartis has received expanded U.S. regulatory approval for its immunology drug, Cosentyx. The Food and Drug Administration (FDA) has cleared the treatment for use in a new, underserved adolescent patient demographic, strengthening a major revenue stream ahead of impending patent expirations elsewhere in the company’s portfolio.

Strengthening the Product Pipeline

This regulatory decision represents a calculated step in Novartis’s ongoing transformation into a focused biopharma entity following the spin-off of its Sandoz generics unit. With blockbuster products such as the heart failure drug Entresto facing near-term patent cliffs, driving volume growth for established brands like Cosentyx has become increasingly critical. Expanding into new niche indications is a central tactic for maintaining operational margins and offsetting future revenue erosion from generic competition.

The latest FDA authorization covers the treatment of adolescents aged 12 and older who suffer from moderate to severe Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition. Cosentyx is now the first IL-17A inhibitor available in the United States for this age group battling the disease. The approval was supported by positive results from the SUNSHINE and SUNRISE Phase III clinical trials, which demonstrated a significant reduction in inflammatory lesions. The safety profile observed was consistent with existing data for adult patients.

Should investors sell immediately? Or is it worth buying Novartis?

Shareholder Returns and Market Performance

Alongside these operational advancements, Novartis continues to emphasize shareholder returns. The company recently raised its dividend to 3.70 CHF per share, marking the 29th consecutive annual increase. While registered shareholders received their payment on March 12, the first installment of the distribution is scheduled for holders of American Depositary Receipts (ADRs) on Monday, March 16.

On the trading floor, the equity has recently entered a phase of mild consolidation despite the positive news. Closing at €134.34 on Friday, the shares trade approximately six percent below their 52-week high recorded at the beginning of the month. Nevertheless, the longer-term upward trend remains firmly intact.

Since the start of the year, the stock has posted a gain of 14.22% and continues to trade well above its 200-day moving average of €113.50. The 50-day moving average, currently at €130.69, now serves as a crucial technical level. If this support holds, the overall chart picture will stay constructive despite the recent weekly decline of 3.27%.